Zhu et al. demonstrated that the JAK2 inhibition through ruxolitinib administration reduces the NLRP3 inflammasome activation through the JAK2/STAT3 pathway, to improve the ischemic stroke damage and neuroinflammation. This evidence concerns the gene JAK2 and ischemic stroke.